Pharmaceuticals News and Research

RSS

Ligand Pharmaceuticals' total revenues for Q4 2013 increase 8% to $14.7 million

Ligand Pharmaceuticals Incorporated today reported financial results for the three and 12 months ended December 31, 2013, and provided an operating forecast and program updates.

11 Feb 2014

Eternity Healthcare developing saliva-based noninvasive sugar monitoring device

Eternity Healthcare Inc., a medical device and diagnostic company specializing in diabetes management, announced today that they are in development of a noninvasive sugar monitoring device using saliva instead of blood. The technology utilizes an ultra sensitive sugar monitor and an additional sensor for salivary amylase enzyme activity.

From Medtronic 11 Feb 2014

Mallinckrodt's subsidiary to acquire all outstanding shares of Cadence Pharmaceuticals

Mallinckrodt plc, a leading global specialty pharmaceuticals company, and Cadence Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt plc will commence a tender offer to acquire all outstanding shares of Cadence Pharmaceuticals, Inc. for $14.00 per share in cash or approximately $1.3 billion on a fully diluted basis, which represents a 32% premium to the trailing 30-trading-day volume weighted average price (VWAP) of $10.62 per share for Cadence Pharmaceuticals, Inc.

11 Feb 2014

Cambrex fourth quarter sales increase 46.3% to $103 million

Cambrex Corporation reports results for the fourth quarter and full year ended December 31, 2013.

11 Feb 2014

Cardiome Pharma's subsidiary signs agreement with Tamro to distribute BRINAVESS in Sweden

Cardiome Pharma Corp. today announced that its subsidiary, Correvio GmbH, has entered into an agreement with Tamro AB, headquartered in Gothenburg, Sweden, to distribute BRINAVESS (vernakalant IV) to customers in the Swedish market.

11 Feb 2014

New hemostasis valve with sideport tubing and stopcock launched by Qosina

...

11 Feb 2014

UPS completes acquisition of U.K.-based Polar Speed

UPS today announced it has completed the purchase of U.K.-based Polar Speed, an innovative provider of temperature-sensitive pharmaceutical supply chain solutions in the U.K. The acquisition further strengthens UPS's healthcare network across Europe, providing healthcare companies access to a single source for logistics solutions across the continent.

11 Feb 2014

Combination of SYK and FLT3 enzymes promotes progression of acute myelogenous leukemia

Reinforcing the need to look beyond genomic alterations to understand the complexity of cancer, researchers from Dana-Farber/Boston Children's Cancer and Blood Disorders Center report that a normal enzyme called SYK pairs with FLT3, the most commonly mutated enzyme found in acute myelogenous leukemia (AML), to promote progression of the disease.

11 Feb 2014

Viewpoints: The debate at AOL about a baby's medical costs; Gov. Jindal says economy's verdict on health law is not good

Late last week, Tim Armstrong, the chief executive officer of AOL, landed himself in a media firestorm when he held a town hall with employees to explain why he was paring their retirement benefits. After initially blaming Obamacare for driving up the company's health care costs, he pointed the finger at an unlikely target: babies. Specifically, my baby. ... ... She weighed 1 pound, 9 ounces. ... I take issue with how he reduced my daughter to a "distressed baby" who cost the company too much money. How he blamed the saving of her life for his decision to scale back employee benefits. How he exposed the most searing experience of our lives, one that my husband and I still struggle to discuss with anyone but each other, for no other purpose than an absurd justification for corporate cost-cutting (Deanna Fei, 2/9)

11 Feb 2014

Targacept completes patient recruitment in TC-5214 Phase 2b study for treatment of overactive bladder

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced that it has completed recruitment of patients in its Phase 2b clinical study of TC-5214 as a treatment for overactive bladder (OAB).

10 Feb 2014

Mallinckrodt announces commercial launch of PENNSAID

Mallinckrodt today announced the commercial launch of PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%). PENNSAID 2% is a topical non-steroidal anti-inflammatory drug (NSAID) approved for use in the treatment of the pain of osteoarthritis of the knees.

10 Feb 2014

NASA signs patent to develop novel biotechnology approaches that could have medical applications

NASA has signed two patent license agreements with GRoK Technologies LLC of Houston to help develop novel biotechnology approaches that could have multiple applications in space and on Earth.

10 Feb 2014

PHT‘s LogPad App System receives Clinical Informatics News Best Practices Award

The PHT Corporation LogPad App System was a finalist for the Clinical Informatics News Best Practices Awards announced February 6 at the SCOPE Summit for Clinical Ops Executives.

10 Feb 2014

pSivida announces financial results for second quarter 2014

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its second quarter ended December 31, 2013.

10 Feb 2014

Novel combined therapy for treatment of septic patients in ICU

Septic shock is caused by excessive and systemic reaction of the entire body against infectious agents, in most cases of bacterial origin. The number of deaths by septic shock in intensive care units is very high and is still increasing, despite numerous large scale clinical trials.

9 Feb 2014

Researcher receives grant to find compounds that interrupt binding of cancer cells to blood vessels

In scary movies, the killer often comes back to life mysteriously, attacking again when the main character least expects it. Blood cancers are like this too, finding a safe spot to hide during treatment and then striking again when a patient is in remission.

7 Feb 2014

Eleven Biotherapeutics announces pricing of initial public offering of common stock

Eleven Biotherapeutics, a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions.

6 Feb 2014

Mallinckrodt’s net sales increase $540.2M to 7.2% in first quarter 2014

Mallinckrodt plc, a global specialty pharmaceutical and medical imaging business, today reported results for the first quarter of fiscal 2014, which ended December 27, 2013. The company also announced revised guidance for fiscal 2014.

6 Feb 2014

Viewpoints: CBO report on health law: Damaging the labor market or freeing workers from 'insurance trap'?

There are 7.8 million Americans working part-time who want full-time work, including a fry cook whose restaurant cut his hours to avoid Affordable Care Act mandates and confronted President Obama in an online Google Q&A last week: "We can't survive. It's not a living." Mr. Obama changed the subject to raising the minimum wage. But he can't dodge reality forever as the evidence piles up that ObamaCare is harming the labor market.

6 Feb 2014

New effective method of treatment against increased cholesterol

Cardiovascular diseases are the number one cause of death globally due to e.g. arteriosclerosis. The cause is increased cholesterol. There is therefore a considerable need for an effective method of treatment against increased cholesterol. Now, Danish researchers have made a discovery that may change the picture of how it must be treated.

5 Feb 2014

Pharmaceuticals News and Research

Ligand Pharmaceuticals' total revenues for Q4 2013 increase 8% to $14.7 million

Eternity Healthcare developing saliva-based noninvasive sugar monitoring device

Mallinckrodt's subsidiary to acquire all outstanding shares of Cadence Pharmaceuticals

Cambrex fourth quarter sales increase 46.3% to $103 million

Cardiome Pharma's subsidiary signs agreement with Tamro to distribute BRINAVESS in Sweden

New hemostasis valve with sideport tubing and stopcock launched by Qosina

UPS completes acquisition of U.K.-based Polar Speed

Combination of SYK and FLT3 enzymes promotes progression of acute myelogenous leukemia

Viewpoints: The debate at AOL about a baby's medical costs; Gov. Jindal says economy's verdict on health law is not good

Targacept completes patient recruitment in TC-5214 Phase 2b study for treatment of overactive bladder

Mallinckrodt announces commercial launch of PENNSAID

NASA signs patent to develop novel biotechnology approaches that could have medical applications

PHT‘s LogPad App System receives Clinical Informatics News Best Practices Award

pSivida announces financial results for second quarter 2014

Novel combined therapy for treatment of septic patients in ICU

Researcher receives grant to find compounds that interrupt binding of cancer cells to blood vessels

Eleven Biotherapeutics announces pricing of initial public offering of common stock

Mallinckrodt’s net sales increase $540.2M to 7.2% in first quarter 2014

Viewpoints: CBO report on health law: Damaging the labor market or freeing workers from 'insurance trap'?

New effective method of treatment against increased cholesterol

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence